Barbara Dalton

Biography

Barbara J. Dalton, Ph.D. joined Pfizer in 2007 to manage the Pfizer Ventures Investments (PVI) team within the Worldwide Business Development organization. Dr. Dalton has 24 years of corporate venture capital experience in the pharmaceutical industry supporting and managing teams involved in direct and indirect healthcare investing. She has had management responsibility for over 100 diverse company investments and 30 fund investments and in both the US and Europe. PVI has invested in over 50 companies pursuing products, technologies and services relevant to all aspects of Pfizer’s business, since inception in 2004. Barbara currently represents PVI’s investments in Ablexis, The Accelerator NYC, Cydan, Imara, Ixchelsis, Levicept, Lodo Therapeutics, Morphic Therapeutics, Petra Pharma and Rhythm Pharmaceuticals. Dr. Dalton began her pharmaceutical career as a research scientist in Immunology at SmithKline and French Laboratories in 1983 and joined their venture capital group, S.R. One, Limited ten years later. Dr. Dalton was also a founding member and General Partner with EuclidSR Partners, a private venture capital firm, where SmithKline (now GSK) was a leading limited partner. Dr. Dalton has been on the board of academic groups, not-for-profit foundations and industry organizations in her role as a member of the BioPharma ecosystem in both the Philadelphia and New York communities. She, along with Brenda Gavin, were instrumental in the creation of the corporate subgroup of the National Venture Capital Association. She is currently the Chairman of the Healthcare Sector of the Partnership Fund for New York City. Dr. Dalton is a graduate of Penn State and received her Ph.D. in Microbiology and Immunology from The Medical College of Pennsylvania (now the Drexel University College of Medical School)

Research Interest

business development